These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19082520)

  • 1. Sulphonylureas and cancer: a case-control study.
    Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
    Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
    Sadikot SM; Mogensen CE
    Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M; Tronko M; Kravchenko V; Kovtun V
    Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
    Galeone F; Fiore G; Arcangeli A; Mannucci E
    Minerva Endocrinol; 1998 Sep; 23(3):71-5. PubMed ID: 10063324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
    Bilinska M; Potocka J; Korzeniowska-Kubacka I; Piotrowicz R
    Coron Artery Dis; 2007 Sep; 18(6):455-62. PubMed ID: 17700217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
    Stefanović V; Antić S; Mitić-Zlatković M; Stojiljković S; Milojković M; Bogicević M; Vlahović P
    Ann Clin Biochem; 2003 May; 40(Pt 3):232-4. PubMed ID: 12803833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
    González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
    J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.